Document is current
Any future updates will be listed below
-
Authors
Zhan, Hui
Cammann, Davis
Cummings, Jeffrey L.
Dong, Xianjun
Chen, Jingchun https://orcid.org/0000-0001-9408-0117
-
Funding
Funding for this research was provided by:
IDSA Foundation (70823173)
Mountain West Clinical and Translational Research Infrastructure Network Program (U54GM104944)
National Institute on Aging (R15AG083618-01A1, R35AG71476, R25AG083721-01)
National Institute of General Medical Sciences (P20GM109025)
National Institute of Neurological Disorders and Stroke (RO1NS139383)
Alzheimer's Drug Discovery Foundation (Alzheimer's Drug Discovery Foundation)
Ted and Maria Quirk Endowment (Ted and Maria Quirk Endowment)
Joy Chambers-Grundy Endowment (Joy Chambers-Grundy Endowment)
- License Information
-
More Information
Article History
Received: 16 December 2024
Accepted: 23 February 2025
First Online: 6 March 2025
Declarations
:
: JLC has provided consultation to Acadia, Acumen, ALZpath, Annovis, Aprinoia, Artery, Biogen, Biohaven, BioXcel, Bristol-Myers Squib, Eisai, Fosun, GAP Foundation, Green Valley, Janssen, Karuna, Kinoxis, Lighthouse, Lilly, Lundbeck, LSP/eqt, Mangrove Therapeutics, Merck, MoCA Cognition, New Amsterdam, Novo Nordisk, Optoceutics, Otsuka, Oxford Brain Diagnostics, Praxis, Prothena, ReMYND, Roche, Scottish Brain Sciences, Signant Health, Simcere, Sinaptica, T-Neuro, TrueBinding, and Vaxxinity pharmaceutical, assessment, and investment companies.
: This study only leveraged summary-level statistics without participant information. The ethics approval has been reported by the cited studies.
: The authors declare that they have no competing interests.
